Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Finland
  4. Nasdaq Helsinki
  5. Nanoform Finland Oyj
  6. News
  7. Summary
    NANOFH   FI4000330972

NANOFORM FINLAND OYJ

(NANOFH)
  Report
Delayed Nasdaq Helsinki  -  10:43 2022-09-27 am EDT
3.220 EUR   -0.92%
09/26Nanoform Finland Oyj : unveils new patient statue
PU
09/18Certain Shares of Nanoform Finland Oyj are subject to a Lock-Up Agreement Ending on 18-SEP-2022.
CI
09/07Nanoform Finland Plc - Manager's transactions - Niklas Sandler
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Nanoform and Pharmanovia to breathe new life into iconic medicines

07/14/2022 | 01:11am EDT

Press release

Nanoform Finland Plc

July 14th, 2022

08:10 a.m. Finnish time / 07:10 a.m. Swedish time

Nanoform and Pharmanovia to breathe new life into iconic medicines

Helsinki, Finland - Nanoform Finland Plc., an innovative nanoparticle medicine-enabling company, today announced that it has partnered with Pharmanovia, a fast-growing specialty pharma business with a portfolio of over 20 branded drugs in 140 markets.

The new strategic partnership aims to add value to branded prescription medicines. Pharmanovia will look to apply Nanoform's proprietary nanoparticle technologies and formulation know-how to leading established pharmaceutical brands.

The partnership starts with an iconic branded medicine where both parties see value in enhancing bioavailability for patient benefit. The value of the stage-gated agreement is according to Nanoform's business model for non-GMP and cGMP work.

"This partnership is a great example of where the power of small can add value for iconic medicines to make them even more effective. Pharmanovia's business model enables brand loyalty to continue from one generation to the next" said Christian Jones, Chief Commercial Officer of Nanoform.

For further information, please contact:

Christian Jones, CCO

Christian.jones@nanoform.com / +44 7804 474771

For investor relations queries, please contact:

Henri von Haartman, Director of Investor Relations

hvh@nanoform.com / +46 7686 650 11

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services. Nanoform's capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information, please visit http://www.nanoform.com

Forward-Looking Statements

This company release contains forward-looking statements, including, without limitation, statements regarding Nanoform's strategy, business plans and focus. The words may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this company release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this company release, including, without limitation, any related to Nanoform's business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines and competition from other companies. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this company release represent Nanoform's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

https://news.cision.com/nanoform/r/nanoform-and-pharmanovia-to-breathe-new-life-into-iconic-medicines,c3600995

https://mb.cision.com/Main/18905/3600995/1604165.pdf

(c) 2022 Cision. All rights reserved., source Press Releases - English

All news about NANOFORM FINLAND OYJ
09/26Nanoform Finland Oyj : unveils new patient statue
PU
09/18Certain Shares of Nanoform Finland Oyj are subject to a Lock-Up Agreement Ending on 18-..
CI
09/07Nanoform Finland Plc - Manager's transactions - Niklas Sandler
AQ
09/06Share subscriptions based on Nanoform Finland Plc's stock options 2-3/2019 and 1/2020
AQ
08/25Transcript : Nanoform Finland Oyj, H1 2022 Earnings Call, Aug 25, 2022
CI
08/25Nanoform Finland Oyj : Interim Report for January-June 2022
PU
08/25Nanoform Q2 And H1 2022 Report : Strong momentum continues
AQ
08/25Nanoform Finland Oyj Reports Earnings Results for the Second Quarter and Six Months End..
CI
08/10Invitation to Nanoform's Interim Report January-June 2022
AQ
07/14Nanoform and Pharmanovia to breathe new life into iconic medicines
AQ
More news
Financials
Sales 2022 5,00 M 4,80 M 4,80 M
Net income 2022 -22,1 M -21,2 M -21,2 M
Net cash 2022 67,5 M 64,8 M 64,8 M
P/E ratio 2022 -11,1x
Yield 2022 -
Capitalization 252 M 242 M 242 M
EV / Sales 2022 37,0x
EV / Sales 2023 13,2x
Nbr of Employees 143
Free-Float 75,2%
Chart NANOFORM FINLAND OYJ
Duration : Period :
Nanoform Finland Oyj Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NANOFORM FINLAND OYJ
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 3,22 €
Average target price 8,88 €
Spread / Average Target 176%
EPS Revisions
Managers and Directors
Edward Hæggström Chief Executive Officer
Albert Häggström Chief Financial Officer & Director
Miguel Maria de Oliveira Barreiros Calado Chairman
Niklas Sandler Chief Technology Officer
Mads Laustsen Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
NANOFORM FINLAND OYJ-50.61%246
JOHNSON & JOHNSON-3.14%435 655
ELI LILLY AND COMPANY12.76%292 179
ROCHE HOLDING AG-19.31%253 262
ABBVIE INC.4.29%249 673
PFIZER, INC.-25.35%245 989